Skip to main content
OpenTrials
Completed

NCT Number: NCT00000281

Pharmacotherapy for Schizophrenic Drug Users - 6

The purpose of this study is to evaluate maintenance neuroleptics for Schizophrenic patients who are cocaine abusers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cocaine-Related Disorders Chemically-Induced Disorders Mental Disorders Shcizophrenia Substance-Related Disorders

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

VA Connecticut Healthcare System

New Haven, Connecticut, 06519, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Please contact site for information.

Treatment and study plan

Amantadine

Behavioral

Primary outcomes

  1. Drug use

  2. Retention

  3. Psychological symptoms

  4. Schizophrenic symptoms

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)
  • VA Connecticut Healthcare System

Registry information

Official study title

Pharmacotherapy for Schizophrenic Drug Users

Important dates

Study start
1994
Primary completion
1999
Study completion
1999
First posted
Sep 21, 1999
Registry last updated
Dec 15, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.